Aclaris Therapeutics Past Earnings Performance
Past criteria checks 0/6
Aclaris Therapeutics's earnings have been declining at an average annual rate of -0.7%, while the Pharmaceuticals industry saw earnings growing at 0.5% annually. Revenues have been growing at an average rate of 43.8% per year.
Key information
-0.7%
Earnings growth rate
15.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 14.1% |
| Revenue growth rate | 43.8% |
| Return on equity | -56.3% |
| Net Margin | -283.1% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Aclaris Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 31 | -88 | 32 | 0 |
| 30 Sep 23 | 21 | -115 | 31 | 0 |
| 30 Jun 23 | 31 | -105 | 30 | 0 |
| 31 Mar 23 | 31 | -96 | 28 | 0 |
| 31 Dec 22 | 30 | -87 | 25 | 0 |
| 30 Sep 22 | 24 | -82 | 25 | 0 |
| 30 Jun 22 | 6 | -83 | 25 | 0 |
| 31 Mar 22 | 6 | -81 | 25 | 0 |
| 31 Dec 21 | 7 | -91 | 24 | 0 |
| 30 Sep 21 | 7 | -82 | 22 | 0 |
| 30 Jun 21 | 7 | -71 | 19 | 0 |
| 31 Mar 21 | 7 | -65 | 19 | 0 |
| 31 Dec 20 | 6 | -51 | 21 | 0 |
| 30 Sep 20 | 6 | -57 | 22 | 0 |
| 30 Jun 20 | 6 | -69 | 25 | 0 |
| 31 Mar 20 | 4 | -102 | 27 | 0 |
| 31 Dec 19 | 4 | -114 | 28 | 0 |
| 30 Sep 19 | 5 | -118 | 27 | 0 |
| 30 Jun 19 | 5 | -115 | 26 | 0 |
| 31 Mar 19 | 6 | -79 | 16 | 0 |
| 31 Dec 18 | 6 | -82 | 26 | 0 |
| 30 Sep 18 | 5 | -81 | 33 | 13 |
| 30 Jun 18 | 5 | -79 | 34 | 24 |
| 31 Mar 18 | 3 | -86 | 45 | 32 |
| 31 Dec 17 | 2 | -50 | 19 | 0 |
| 30 Sep 17 | 1 | -57 | 25 | 33 |
| 30 Jun 17 | 0 | -50 | 20 | 30 |
| 31 Mar 17 | 0 | -48 | 16 | 31 |
| 31 Dec 16 | 0 | -48 | 15 | 33 |
| 30 Sep 16 | 0 | -42 | 13 | 25 |
| 30 Jun 16 | 0 | -42 | 10 | 28 |
| 31 Mar 16 | 0 | -33 | 8 | 19 |
| 31 Dec 15 | 0 | -23 | 5 | 15 |
| 30 Sep 15 | 0 | -21 | 3 | 15 |
| 30 Jun 15 | 0 | -13 | 3 | 8 |
| 31 Mar 15 | 0 | -12 | 2 | 7 |
| 31 Dec 14 | 0 | -11 | 2 | 7 |
Quality Earnings: 0H8T is currently unprofitable.
Growing Profit Margin: 0H8T is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0H8T is unprofitable, and losses have increased over the past 5 years at a rate of 0.7% per year.
Accelerating Growth: Unable to compare 0H8T's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0H8T is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (3.5%).
Return on Equity
High ROE: 0H8T has a negative Return on Equity (-56.29%), as it is currently unprofitable.